InSightec Ltd. Announces US$30 Million Investment Round

TIRAT CARMET, Israel, November 29 /PRNewswire/ --     InSightec Ltd. today reported that it has closed an internal round of 
financing totaling US$30 million from its existing investors: Elbit Imaging 
Ltd. (Nasdaq: EMITF), GE Capital Equity Holdings Inc., a subsidiary of 
General Electric Company (NYSE: GE), MediTech Advisors LLC ("MTA"), a private 
firm specializing in the healthcare marketplace, and directors and managers 
of the company.

The investment will take the form of Preferred Shares, which are
convertible to InSightec's ordinary shares subject to the fulfillment of
certain conditions stipulated in the agreement.

InSightec reported that the funds would be used to expand its research
and development efforts, for marketing and sales activities, and for general
corporate purposes.

InSightec's President and CEO Dr. Kobi Vortman said, "The ExAblate(r)
2000 treatments of uterine fibroids continue to grow globally with excellent
clinical results driving market adoption and with more than 50 leading sites
globally. In parallel InSightec is expanding the research into oncology
areas: bone metastases, prostate cancer, breast cancer, liver tumors and
brain tumors. InSightec has received the European CE approval for pain
palliation of bone metastases based on clinical results demonstrating that
this technology has the potential to become an important treatment
alternative for this patient population and also received from the FDA IDE
approval for starting a phase III clinical trial in the US for the treatment
of bone metastases. The investment will allow acceleration of the technical
and clinical research for oncology applications providing improved care for
patients around the world.

The continued support by our current investors is a vote of confidence in
the employees, the technology and the vision, and we are proud in it."

About InSightec

InSightec Ltd. is a privately held company owned by Elbit Imaging, 
General Electric, MediTech Advisors, LLC and employees. It was founded in 
1999 to develop the breakthrough MR guided Focused Ultrasound technology and
transform it into the next generation operating room. Headquartered near
Haifa, Israel, the company has over 150 employees and has invested more than
US$100 million in research, development, and clinical investigations. Its U.S.
headquarters are located in Dallas, Texas. For more information, please go
to: http://www.insightec.com/

About ExAblate

The ExAblate(r) is the first system to use the breakthrough MRgFUS 
technology that combines MRI - to visualize tissues in the body, plan the 
treatment and monitor treatment outcome in real time - and high intensity 
focused ultrasound to thermally ablate tumors inside the body non-invasively. 
MR thermometry, provided uniquely by the system, allows the physician to 
control and adjust the treatment in real time to ensure that the targeted 
tumor is fully treated and surrounding tissue is spared. ExAblate received 
FDA approval for the treatment of symptomatic uterine fibroids in October 
2004. ExAblate has been recognized for its innovation and potential to serve
mankind and has been awarded the 2004 European Union's Information Society
Technologies grand prize, The Wall Street Journal's 2004 Technology
Innovation Awards, Advanced Imaging's 2005 Solutions of the Year, the Red
Herring 100 Europe 2007 Award.

Contact Information:
    InSightec Ltd.
    http://www.insightec.com
    Tel: +972-4-813-1313
    Email: info@insightec.com

    For media inquiries:
    Fern Lazar
    Lazar Partners, Ltd.
    Tel: +1-212-867-1762
    Email: flazar@lazarpartners.com